{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:35:49Z","timestamp":1767922549886,"version":"3.49.0"},"reference-count":61,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2024,3,5]]},"DOI":"10.18632\/oncotarget.28558","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T13:28:09Z","timestamp":1709645289000},"page":"159-174","source":"Crossref","is-referenced-by-count":3,"title":["GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells"],"prefix":"10.18632","volume":"15","author":[{"given":"Laurence","family":"Booth","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"West","sequence":"additional","affiliation":[{"name":"Genzada Pharmaceuticals, Hutchinson, KS 67502, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Dent","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"1","volume-title":"StatPearls","author":"Azevedo","year":"2024"},{"key":"2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-3-540-85772-3_2","article-title":"Epidemiology of multiple myeloma","volume":"18","author":"Becker","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ijc.22718","article-title":"Multiple myeloma: a review of the epidemiologic literature","volume":"12","author":"Trichopoulos","year":"2007","journal-title":"Int J Cancer"},{"key":"4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/hon.3045","article-title":"Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells","volume":"4","author":"Grant","year":"2022","journal-title":"Hematol Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/107327480301000502","article-title":"Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers","volume":"1","author":"Anderson","year":"2003","journal-title":"Cancer Control"},{"key":"6","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-13-0755","article-title":"U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma","volume":"1","author":"Adams","year":"2013","journal-title":"Clin Cancer Res"},{"key":"7","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1002\/cpt.3057","article-title":"CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented Review","volume":"11","author":"Mailankody","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/10428194.2023.2276676","article-title":"BCMA CAR-T cells in multiple myeloma-ready for take-off?","volume":"6","author":"Danhof","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"9","doi-asserted-by":"publisher","first-page":"9710","DOI":"10.3390\/curroncol30110705","article-title":"Multiple Myeloma in 2023 Ways: From Trials to Real Life","volume":"3","author":"Sapuppo","year":"2023","journal-title":"Curr Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jtct.2023.10.022","article-title":"Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"3","author":"Pasquini","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"11","doi-asserted-by":"publisher","first-page":"12163","DOI":"10.1038\/s41598-018-29683-1","article-title":"Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds","volume":"8","author":"Tsue","year":"2018","journal-title":"Sci Rep"},{"key":"12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.38212\/2224-6614.3454","article-title":"The therapeutic potential of curcumin and its related substances in turmeric: From raw material selection to application strategies","volume":"3","author":"Pan","year":"2023","journal-title":"J Food Drug Anal"},{"key":"13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/pharmaceutics15041275","article-title":"Exploring the Contribution of Curcumin to Cancer Therapy: A Systematic Review of Randomized Controlled Trials","volume":"1","author":"Mancuso","year":"2023","journal-title":"Pharmaceutics"},{"key":"14","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.1002\/jcp.29580","article-title":"(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo","volume":"23","author":"Hancock","year":"2020","journal-title":"J Cell Physiol"},{"key":"15","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.1002\/jcp.29464","article-title":"GZ17-6.02 initiates DNA damage causing autophagosome-dependent HDAC degradation resulting in enhanced anti-PD1 checkpoint inhibitory antibody efficacy","volume":"23","author":"Dent","year":"2020","journal-title":"J Cell Physiol"},{"key":"16","doi-asserted-by":"publisher","first-page":"711043","DOI":"10.3389\/fonc.2021.711043","article-title":"GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins","volume":"1","author":"Dent","year":"2021","journal-title":"Front Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"656453","DOI":"10.3389\/fonc.2021.656453","article-title":"GZ17-6.02 Interacts With [MEK1\/2 and B-RAF Inhibitors] to Kill Melanoma Cells","volume":"1","author":"Dent","year":"2021","journal-title":"Front Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.18632\/oncotarget.28177","article-title":"GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells","volume":"1","author":"Dent","year":"2022","journal-title":"Oncotarget"},{"key":"19","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/09546634.2020.1764905","article-title":"A novel plant-derived compound is synergistic with 5-fluorouracil and has increased apoptotic activity through autophagy in the treatment of actinic keratoses","volume":"3","author":"Dent","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/CAD.0000000000001425","article-title":"A novel combination of isovanillin, curcumin, and harmine (GZ17-6.02) enhances cell death and alters signaling in actinic keratoses cells when compared to individual components and two-component combinations","volume":"3","author":"Dent","year":"2023","journal-title":"Anticancer Drugs"},{"key":"21","doi-asserted-by":"publisher","first-page":"1045459","DOI":"10.3389\/fonc.2022.1045459","article-title":"GZ17-6.02 kills prostate cancer cellsand","volume":"1","author":"Dent","year":"2022","journal-title":"Front Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/CAD.0000000000001203","article-title":"Mechanisms of GZ17-6.02 resistance","volume":"3","author":"Dent","year":"2022","journal-title":"Anticancer Drugs"},{"key":"23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3389\/fonc.2020.01331","article-title":"GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling","volume":"1","author":"Dent","year":"2020","journal-title":"Front Oncol"},{"key":"24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jep.2016.04.038","article-title":"Complementary and alternative medicine use among cancer patients in Palestine with special reference to safety-related concerns","volume":"18","author":"Hamadeh","year":"2016","journal-title":"J Ethnopharmacol"},{"key":"25","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1080\/15384047.2015.1078021","article-title":"Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells","volume":"1","author":"Jiang","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/ptr.2860","article-title":"The beta-carboline alkaloid harmine inhibits BCRP and can reverse resistance to the anticancer drugs mitoxantrone and camptothecin in breast cancer cells","volume":"2","author":"Wink","year":"2010","journal-title":"Phytother Res"},{"key":"27","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.freeradbiomed.2007.08.018","article-title":"Structure-activity relationship of C6-C3 phenylpropanoids on xanthine oxidase-inhibiting and free radical-scavenging activities","volume":"4","author":"Lin","year":"2007","journal-title":"Free Radic Biol Med"},{"key":"28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0027-5107(01)00294-9","article-title":"Genotoxic and recombinogenic activities of the two beta-carboline alkaloids harman and harmine in Saccharomyces cerevisiae","volume":"50","author":"Henriques","year":"2002","journal-title":"Mutat Res"},{"key":"29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jep.2017.03.049","article-title":"A review on traditional uses, phytochemistry, pharmacology, pharmacokinetics and toxicology of the genus Peganum","volume":"20","author":"Wang","year":"2017","journal-title":"J Ethnopharmacol"},{"key":"30","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1182\/bloodadvances.2022008241","article-title":"TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy","volume":"7","author":"Cai","year":"2023","journal-title":"Blood Adv"},{"key":"31","doi-asserted-by":"publisher","first-page":"106967","DOI":"10.1016\/j.leukres.2022.106967","article-title":"LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma","volume":"12","author":"Shen","year":"2022","journal-title":"Leuk Res"},{"key":"32","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1186\/s12885-022-09775-y","article-title":"Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK","volume":"2","author":"Appelmann","year":"2022","journal-title":"BMC Cancer"},{"key":"33","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/cells10123464","article-title":"The Role of Chaperone-Mediated Autophagy in Bortezomib Resistant Multiple Myeloma","volume":"1","author":"Ling","year":"2021","journal-title":"Cells"},{"key":"34","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/s41388-021-02167-9","article-title":"Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1","volume":"4","author":"Liu","year":"2022","journal-title":"Oncogene"},{"key":"35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/1440-1681.13643","article-title":"Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma","volume":"4","author":"Chen","year":"2022","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41419-022-04629-8","article-title":"NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma","volume":"1","author":"Cai","year":"2022","journal-title":"Cell Death Dis"},{"key":"37","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.18632\/oncotarget.26704","article-title":"Super-enhancers: novel target for pancreatic ductal adenocarcinoma","volume":"1","author":"Dhar","year":"2019","journal-title":"Oncotarget"},{"key":"38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/bjh.17080","article-title":"Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma","volume":"19","author":"Spencer","year":"2021","journal-title":"Br J Haematol"},{"key":"39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3892\/ol.2019.10301","article-title":"Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner","volume":"1","author":"Zhao","year":"2019","journal-title":"Oncol Lett"},{"key":"40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/0008-5472.CAN-21-0921","article-title":"Super Enhancer-Mediated Upregulation of HJURP Promotes Growth and Survival of t(4;14)-Positive Multiple Myeloma","volume":"8","author":"Lim","year":"2022","journal-title":"Cancer Res"},{"key":"41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.theriogenology.2023.05.018","article-title":"Transcription factor ELK1 regulates the expression of histone 3 lysine 9 to affect developmental potential of porcine preimplantation embryos","volume":"20","author":"Li","year":"2023","journal-title":"Theriogenology"},{"key":"42","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.3390\/cancers14133270","article-title":"Diverse Functions of KDM5 in Cancer: Transcriptional Repressor or Activator?","volume":"1","author":"Ohguchi","year":"2022","journal-title":"Cancers (Basel)"},{"key":"43","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.cell.2019.02.002","article-title":"Mechanism of Cross-talk between H2B Ubiquitination and H3 Methylation by Dot1L","volume":"17","author":"Wolberger","year":"2019","journal-title":"Cell"},{"key":"44","first-page":"2159","article-title":"Histone methyltransferases: novel targets for tumor and developmental defects","volume":"7","author":"Jiang","year":"2015","journal-title":"Am J Transl Res"},{"key":"45","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1093\/nar\/gku242","article-title":"Histone H3 K79 methylation states play distinct roles in UV-induced sister chromatid exchange and cell cycle checkpoint arrest in Saccharomyces cerevisiae","volume":"4","author":"Thompson","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"46","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.cell.2015.10.002","article-title":"Histone H3 Threonine Phosphorylation Regulates Asymmetric Histone Inheritance in the Drosophila Male Germline","volume":"16","author":"Chen","year":"2015","journal-title":"Cell"},{"key":"47","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.cub.2011.03.047","article-title":"PP1\/Repo-man dephosphorylates mitotic histone H3 at T3 and regulates chromosomal aurora B targeting","volume":"2","author":"Bollen","year":"2011","journal-title":"Curr Biol"},{"key":"48","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1093\/nar\/gkq147","article-title":"Chromatin methylation activity of Dnmt3a and Dnmt3a\/3L is guided by interaction of the ADD domain with the histone H3 tail","volume":"3","author":"Jeltsch","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"49","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.cub.2013.05.017","article-title":"Aurora B defines its own chromosomal targeting by opposing the recruitment of the phosphatase scaffold Repo-Man","volume":"2","author":"Bollen","year":"2013","journal-title":"Curr Biol"},{"key":"50","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1038\/s41598-019-39672-7","article-title":"Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop","volume":"9","author":"Dimopoulos","year":"2019","journal-title":"Sci Rep"},{"key":"51","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.canlet.2016.09.030","article-title":"Repression of Mcl-1 and disruption of the Mcl-1\/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis","volume":"38","author":"Amiot","year":"2016","journal-title":"Cancer Lett"},{"key":"52","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.3892\/ol.2016.5005","article-title":"V8 induces apoptosis and the endoplasmic reticulum stress response in human multiple myeloma RPMI 8226 cells via the PERK-eIF2\u03b1-ATF4 signaling pathway","volume":"1","author":"Li","year":"2016","journal-title":"Oncol Lett"},{"key":"53","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/15548627.2015.1052928","article-title":"A plastic SQSTM1\/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells","volume":"1","author":"Cenci","year":"2015","journal-title":"Autophagy"},{"key":"54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.exphem.2023.04.004","article-title":"MST1 downregulates TAZ tumor suppressor protein in multiple myeloma and is a potential therapeutic target","volume":"12","author":"Reiman","year":"2023","journal-title":"Exp Hematol"},{"key":"55","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3390\/cancers13081981","article-title":"New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges","volume":"1","author":"Gangemi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"56","doi-asserted-by":"publisher","first-page":"502","DOI":"10.3390\/cells8050502","article-title":"The Roles of Hippo Signaling Transducers Yap and Taz in Chromatin Remodeling","volume":"8","author":"Link","year":"2019","journal-title":"Cells"},{"key":"57","doi-asserted-by":"publisher","first-page":"1900860","DOI":"10.1002\/advs.201900860","article-title":"PINK1-Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B-Mediated Hippo-YAP\/TAZ Pathway","volume":"7","author":"Kang","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"58","doi-asserted-by":"publisher","first-page":"e02564","DOI":"10.7554\/eLife.02564","article-title":"The Hippo effector Yorkie activates transcription by interacting with a histone methyltransferase complex through Ncoa6","volume":"3","author":"Pan","year":"2014","journal-title":"Elife"},{"key":"59","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.celrep.2014.06.017","article-title":"Yorkie promotes transcription by recruiting a histone methyltransferase complex","volume":"8","author":"Irvine","year":"2014","journal-title":"Cell Rep"},{"key":"60","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/1541-7786.MCR-19-0375","article-title":"The Emerging Role of YAP\/TAZ in Tumor Immunity","volume":"1","author":"Niu","year":"2019","journal-title":"Mol Cancer Res"},{"key":"61","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.molcel.2021.01.010","article-title":"Interferon-\u03b3 induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation","volume":"8","author":"Guo","year":"2021","journal-title":"Mol Cell"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T13:28:15Z","timestamp":1709645295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3,5]]}},"alternative-id":["28558"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28558","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}